

Maria João Bonifácio

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4685198/publications.pdf>

Version: 2024-02-01

18
papers

729
citations

840776

11
h-index

839539

18
g-index

19
all docs

19
docs citations

19
times ranked

659
citing authors

#	ARTICLE	IF	CITATIONS
1	Metabolism and disposition of opicapone in the rat and metabolic enzymes phenotyping. <i>Pharmacology Research and Perspectives</i> , 2022, 10, e00891.	2.4	4
2	Absorption, metabolism and excretion of opicapone in human healthy volunteers. <i>British Journal of Clinical Pharmacology</i> , 2022, , .	2.4	4
3	Opicapone enhances the reversal of MPTP-induced Parkinson-like syndrome by levodopa in cynomolgus monkeys. <i>European Journal of Pharmacology</i> , 2021, 892, 173742.	3.5	4
4	Preclinical pharmacological evaluation of the fatty acid amide hydrolase inhibitor BIA 102474. <i>British Journal of Pharmacology</i> , 2020, 177, 2123-2142.	5.4	11
5	Inhibition of catechol-O-methyltransferase in the cynomolgus monkey by opicapone after acute and repeated administration. <i>Neuropharmacology</i> , 2018, 143, 282-288.	4.1	4
6	Discovery of a Potent, Long-Acting, and CNS-Active Inhibitor (BIA 102474) of Fatty Acid Amide Hydrolase. <i>ChemMedChem</i> , 2018, 13, 2177-2188.	3.2	21
7	A single- and multiple-dose study to investigate the pharmacokinetics and pharmacodynamics of opicapone, a novel COMT inhibitor, in rat. <i>Neuropharmacology</i> , 2017, 125, 146-155.	4.1	6
8	Effect of opicapone multiple-dose regimens on levodopa pharmacokinetics. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 540-553.	2.4	14
9	Synthesis and structure-activity relationships of ionizable 1,3,4-oxadiazol-2(3H)-ones as peripherally selective FAAH inhibitors with improved aqueous solubility. <i>Pure and Applied Chemistry</i> , 2016, 88, 341-347.	1.9	3
10	Pharmacological profile of opicapone, a third-generation nitrocatechol catechol-O-methyl transferase inhibitor, in the rat. <i>British Journal of Pharmacology</i> , 2015, 172, 1739-1752.	5.4	50
11	Brain and peripheral pharmacokinetics of levodopa in the cynomolgus monkey following administration of opicapone, a third generation nitrocatechol COMT inhibitor. <i>Neuropharmacology</i> , 2014, 77, 334-341.	4.1	37
12	Pharmacokinetics, Pharmacodynamics and Tolerability of Opicapone, a Novel Catechol-O-Methyltransferase Inhibitor, in Healthy Subjects. <i>Clinical Pharmacokinetics</i> , 2013, 52, 139-151.	3.5	79
13	Opicapone: a short lived and very long acting novel catechol-O-methyltransferase inhibitor following multiple dose administration in healthy subjects. <i>British Journal of Clinical Pharmacology</i> , 2013, 76, 763-775.	2.4	76
14	Computation of the binding affinities of catechol-O-methyltransferase inhibitors: Multisubstate relative free energy calculations. <i>Journal of Computational Chemistry</i> , 2012, 33, 970-986.	3.3	51
15	Design, synthesis, and structure-activity relationships of 1,3,4-oxadiazol-2(3H)-ones as novel FAAH inhibitors. <i>MedChemComm</i> , 2011, 2, 889.	3.4	17
16	Discovery of a Long-Acting, Peripherally Selective Inhibitor of Catechol-O-methyltransferase. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 3396-3411.	6.4	156
17	Catechol-O-methyltransferase and Its Inhibitors in Parkinson's Disease. <i>CNS Neuroscience & Therapeutics</i> , 2007, 13, 352-379.	4.0	166
18	Kinetic inhibitory profile of BIA 3-202, a novel fast tight-binding, reversible and competitive catechol-O-methyltransferase inhibitor. <i>European Journal of Pharmacology</i> , 2003, 460, 163-170.	3.5	26